NMN Interactions: Alcohol, Caffeine, Food & Other Compounds

What "interaction" means in the NMN literature

Questions about nicotinamide mononucleotide (NMN) alongside other substances tend to fall into four groups: alcohol, caffeine, food and fasting states, and other supplements or drugs. The published record answers these groups very unevenly. A 2023 review in Current Nutrition Reports discussed NMN and nicotinamide riboside (NR) as NAD+ precursors with a potential dietary contribution to health (PMID 37273100), while most other available work is preclinical — cell systems, rodent models and structural biology — and was designed to interrogate NAD+ biology rather than to test one compound against another. This page describes what those studies examined and states plainly where no interaction study exists. This page is for educational purposes only and is not medical advice; consult a licensed physician about any question involving health, medications or supplements.

Why a mechanism is not an interaction finding

When no combination has been formally tested, researchers reason from pathways: which enzymes handle a compound, which cofactor pools it draws on, and whether two agents converge on the same step. That reasoning generates hypotheses, not measurements. Throughout this page, such passages are labelled explicitly as mechanistic reasoning so they are not confused with reported results. Formal combination testing looks different — for example, researchers used high-throughput combination drug screening to identify therapeutic strategies for diffuse midline glioma (PMID 31748226), a design in which pairs of agents are deliberately dosed together and compared with each agent alone. No equivalent screen pairing NMN with alcohol, caffeine or common supplements appears in the literature summarised here.

NMN and alcohol: what the studies examined

The most directly relevant published work is a 2025 study in Science Advances, in which researchers reported that hepatic NMNAT1 was required to defend against alcohol-associated fatty liver disease (PMID 40577472). NMNAT1 is the nuclear enzyme that converts NMN into NAD+, so this sits directly on the pathway that NMN feeds. Importantly, the study's experimental variable was the enzyme itself in a liver-disease model, not oral NMN administered alongside alcohol in people.

The mechanistic reasoning that frames this line of work — that hepatic NAD+ availability matters during alcohol exposure — is precisely what the NMNAT1 experiments set out to interrogate (PMID 40577472). Researchers in the NAD+ field frequently extend that reasoning to precursors, since NMN is the substrate the enzyme acts on, but extension is not evidence.

What is absent is easy to state: among the verified papers, no human trial examined NMN with alcohol co-ingestion, no pharmacokinetic study measured NMN absorption or clearance during alcohol exposure, and no controlled study reported adverse events for that combination. Readers encountering confident claims in either direction about NMN and drinking should note that the underlying citation, in this evidence set, is an enzyme-knockout liver study (PMID 40577472) rather than a combination trial.

NMN and caffeine: no study in this evidence set examined the pair

Plainly: none of the verified papers tested caffeine together with NMN, in humans or in animals. There is no reported effect on absorption, no reported change in NAD+ response, and no reported adverse-event signal, because no such experiment appears in this literature.

Mechanistic reasoning (not a finding): researchers describe NMN as entering NAD+ biosynthesis through dedicated enzymes such as NMNAT1 (PMID 40577472) and discuss NMN and NR chiefly as dietary NAD+ precursors (PMID 37273100). Because those enzymes are not the pathways usually invoked for caffeine handling, the default mechanistic expectation stated in reviews of NAD+ precursors is that the two occupy separate metabolic routes — an expectation, not a tested result. Any statement about how a caffeinated beverage changes NMN pharmacokinetics is, at present, unsupported by the studies cited here.

NMN, food and fasting

NMN present in foods and plants

The dietary angle has actually been measured. The 2023 review in Current Nutrition Reports considered the potential dietary contribution of NMN and NR to health, framing both as precursors obtainable in part from food (PMID 37273100). Separately, a 2022 analysis in Molecules reported that Cinnamomum verum J. Presl bark contains high contents of NMN (PMID 36296647), one of the few published quantifications of NMN in a botanical source.

Diet composition inside NMN animal studies

Several rodent studies used diet as part of the disease model rather than as an interaction variable. In a 2025 report in Communications Biology, researchers reported that NMN treatment improved spermatogenesis in obese mice by reducing lysine acetylation of lactate dehydrogenase C (PMID 41298813). A 2024 Circulation Research study reported that glycolysis-mediated activation of v-ATPase by NMN ameliorated lipid-induced cardiomyopathy by repressing the CD36–TLR4 axis (PMID 38422177). In both cases the dietary lipid load created the pathology being studied; neither study compared NMN given with a meal against NMN given without one.

Fasting, meal timing and time of day

No verified study compared fasted and fed NMN administration, tested morning versus evening dosing, or examined NMN during intermittent fasting protocols. Mechanistic reasoning (not a finding): because NAD+ precursors are discussed in reviews as nutrients with a dietary route of entry (PMID 37273100), researchers hypothesise that gastrointestinal conditions and nutritional state could influence precursor handling — a hypothesis that the cited literature does not resolve either way.

NMN alongside other compounds

NAMPT-targeting agents

The clearest pharmacological convergence in the cited set involves NAMPT, the enzyme that produces NMN inside cells. A 2026 European Journal of Medicinal Chemistry report described GD2-directed NAMPT inhibition using antibody–drug conjugates in neuroblastoma (PMID 41707282), an oncology strategy built on depleting NAD+ in tumour cells. Mechanistic reasoning (not a finding): because NMN is the product of the reaction that NAMPT inhibitors block, the two act on the same step of the salvage pathway, which is why NAD+-depletion oncology papers treat precursor availability as a variable of interest (PMID 41707282). The conjugate study itself examined the inhibitor construct, not co-administered NMN.

SARM1, an NMN-responsive enzyme

A 2022 Molecular Cell study reported the structural basis of SARM1 activation, substrate recognition and inhibition by small molecules (PMID 35334231). SARM1 is an NAD+-consuming enzyme central to axon degeneration research. Mechanistic reasoning (not a finding): because this enzyme is repeatedly discussed in relation to the balance between NMN and NAD+, its structural characterisation (PMID 35334231) is often invoked in arguments about what shifting precursor levels might do in nerve tissue. No study in this set measured that scenario with administered NMN in an interaction design.

The NADPH branch and redox-active compounds

A 2025 paper in Antioxidants reported that NADK governs ferroptosis susceptibility by orchestrating NADPH homeostasis (PMID 41462596). NAD kinase sits downstream of the NAD+ pool that precursors feed. Mechanistic reasoning (not a finding): this downstream branch is the usual basis for speculation about NMN alongside antioxidants or iron-related agents, but the cited study examined NADK and NADPH homeostasis rather than NMN combinations (PMID 41462596).

Microbial NMN-sensing elements

Structural work published in Nucleic Acids Research in 2023 investigated the NAD+-II riboswitch, an RNA element that recognises NAD+-related ligands in bacteria (PMID 36610789). This is sometimes cited in discussions of gut-microbiome handling of precursors. As reasoning, it establishes only that NMN-related molecules are recognised by bacterial regulatory elements; it reports nothing about human supplementation or about NMN combined with antibiotics or probiotics.

Combinations that were actually tested — with non-drug variables

One published combination is not pharmacological at all: a 2025 study in Animal Reproduction Science reported that an NMN supplement combined with prolonging maturation time improved the quality of oocytes cultured in vitro (PMID 41240450). Other single-agent preclinical work provides context for what NMN has been examined for — for instance, a 2024 Theranostics study reported that NMN enhanced fracture healing by promoting skeletal stem cell proliferation (PMID 39346542) — but these were not interaction experiments.

Evidence map

Adverse Events in NMN Combination Research: What Studies Report

No human adverse-event data for NMN combined with alcohol, caffeine, food timing or other supplements appear in the verified literature summarised here. The papers cited were structural, mechanistic or preclinical efficacy studies with endpoints such as fracture healing in a rodent model (PMID 39346542) or oocyte quality in culture (PMID 41240450), and they did not report tolerability outcomes for co-administration in people. The 2023 review of NMN and NR as dietary NAD+ precursors is the broadest human-facing source in this set (PMID 37273100); it addressed dietary contribution rather than combination safety. Absence of reported events in studies that never looked for them is not the same as an absence of risk.

Limitations of this evidence base

• Species and system gaps: mouse liver, mouse testis, cultured oocytes and purified proteins do not translate directly to people, as in the NMNAT1 alcohol-liver work (PMID 40577472).
• Design mismatch: pathway studies such as NAMPT-inhibitor conjugates (PMID 41707282) and NADK-ferroptosis work (PMID 41462596) explain plausibility, not outcomes of combined use.
• Unmeasured variables: meal state, timing, alcohol dose and caffeine dose were not manipulated in any cited study.
• Food-content data are narrow: one botanical quantification of NMN in cinnamon bark (PMID 36296647) does not describe typical dietary exposure.

References

• NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health (Current Nutrition Reports, 2023)
• Hepatic NMNAT1 is required to defend against alcohol-associated fatty liver disease (Science Advances, 2025)
• Cinnamomum verum J. Presl Bark Contains High Contents of Nicotinamide Mononucleotide (Molecules, 2022)
• Nicotinamide mononucleotide treatment improves spermatogenesis in obese mice by reducing lysine acetylation of lactate dehydrogenase C (Communications Biology, 2025)
• Glycolysis-Mediated Activation of v-ATPase by Nicotinamide Mononucleotide Ameliorates Lipid-Induced Cardiomyopathy by Repressing the CD36-TLR4 Axis (Circulation Research, 2024)
• GD2-directed NAMPT inhibition using antibody-drug conjugates in neuroblastoma (European Journal of Medicinal Chemistry, 2026)
• Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening (Science Translational Medicine, 2019)
• Structural basis of SARM1 activation, substrate recognition, and inhibition by small molecules (Molecular Cell, 2022)
• NADK Governs Ferroptosis Susceptibility by Orchestrating NADPH Homeostasis (Antioxidants, 2025)
• Structure-based investigations of the NAD+-II riboswitch (Nucleic Acids Research, 2023)
• Nicotinamide mononucleotide supplement combined with prolonging maturation time improves the quality of oocytes cultured in vitro (Animal Reproduction Science, 2025)
• Nicotinamide mononucleotide enhances fracture healing by promoting skeletal stem cell proliferation (Theranostics, 2024)